Figure 2

CP extract prevents pancreatic β cell mass decrease in diabetic mice. The type 2 diabetic mice were induced by feeding with high-fat diet for 4 weeks and then injecting intraperitoneally with 25 mg/kg STZ for 3 days consecutively. The diabetic mice with consecutive 7-day hyperglycemia (11 mmol/L or greater) were selected for the experiment and then CP extract or glibenclamide were administered to mice for consecutive 5 weeks. At the end of experiment, mice were sacrificed. The samples of blood and pancreas tissues were collected. (A) Relative weight of wet pancreas; (C) Histopathological examination of pancrease tissues (H & E staining) (magnification, 100×) and (E) Immunofluorescence (IF) analysis of insulin-positive cell using insulin marker (magnification, 600×). (B) Blood insulin levels; (D) Relative islets area in total pancreatic area; (F) Insulin-positive cell intensity. Blood insulin levels were assayed using commercially available kits (Wuhan Fine Biotech Co. Ltd, China). All data are presented as means ± SEM (n = 8). ^#p < 0.05, ^##p < 0.01 and ^###p < 0.001, diabetic model group compared with non-diabetic groups; ^*p < 0.05, ^**p < 0.01 and ^***p < 0.001, compared with diabetic model group. CON: non-diabetic control group; CON-CP: CP extract-treated non-diabetic control group; MOD: diabetic model group; GLB: glibenclamide-treated diabetic group.